Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. (Q34798892)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. |
scientific article |
Statements
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven (English)
Alison H M Reid
Timothy A Yap
Sarah Settatree
Mary Barrett
Christopher Parker
Vanessa Martins
Elizabeth Folkerd
Jeremy Clark
Colin S Cooper
Stan B Kaye
David Dearnaley
Gloria Lee
Johann S de Bono